Prognostic Value of Sarcopenia and Metabolic Parameters of (18)F-FDG-PET/CT in Patients with Advanced Gastroesophageal Cancer

We investigated the prognostic value of sarcopenia measurements and metabolic parameters of primary tumors derived from (18)F-FDG-PET/CT among patients with primary, metastatic esophageal and gastroesophageal cancer. A total of 128 patients (26 females; 102 males; mean age 63.5 ± 11.7 years; age range: 29–91 years) with advanced metastatic gastroesophageal cancer who underwent (18)F-FDG-PET/CT as part of their initial staging between November 2008 and December 2019 were included. Mean and maximum standardized uptake value (SUV) and SUV normalized by lean body mass (SUL) were measured. Skeletal muscle index (SMI) was measured at the level of L3 on the CT component of the (18)F-FDG-PET/CT. Sarcopenia was defined as SMI < 34.4 cm(2)/m(2) in women and <45.4 cm(2)/m(2) in men. A total of 60/128 patients (47%) had sarcopenia on baseline (18)F-FDG-PET/CT. Mean SMI in patients with sarcopenia was 29.7 cm(2)/m(2) in females and 37.5 cm(2)/m(2) in males. In a univariable analysis, ECOG (<0.001), bone metastases (p = 0.028), SMI (p = 0.0075) and dichotomized sarcopenia score (p = 0.033) were significant prognostic factors for overall survival (OS) and progression-free survival (PFS). Age was a poor prognostic factor for OS (p = 0.017). Standard metabolic parameters were not statistically significant in the univariable analysis and thus were not evaluated further. In a multivariable analysis, ECOG (p < 0.001) and bone metastases (p = 0.019) remained significant poor prognostic factors for OS and PFS. The final model demonstrated improved OS and PFS prognostication when combining clinical parameters with imaging-derived sarcopenia measurements but not metabolic tumor parameters. In summary, the combination of clinical parameters and sarcopenia status, but not standard metabolic values from (18)F-FDG-PET/CT, may improve survival prognostication in patients with advanced, metastatic gastroesophageal cancer.